Merck Wins First Approval For PCSK9 Cholesterol Pill Lipfendra
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Merck has received the first-ever approval for a PCSK9 pill to lower LDL cholesterol, marking a significant milestone in the pharmaceutical industry. This approval initiates a new competitive landscape with existing injection-makers in the cholesterol-lowering market.
The speedy clearance of Lipfendra is an important milestone for Merck, as it positions the company to challenge traditional injection therapies that have dominated the market for lowering LDL cholesterol.
Merck
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.”
IBD — Dow Jones' Merck Snags A First-Of-Its-Kind Approval, And Jumps“The speedy clearance of Lipfendra is an important milestone fo”
biopharma dive — Merck wins first approval of a PCSK9 cholesterol pill